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Abstract
The National Health and Nutrition Examination Survey (NHANES) collects information on 
human papillomavirus (HPV) vaccination history as well as sexual activity. We evaluated data 
from NHANES to assess report of HPV vaccination with ≥1 dose and 3 doses among females and 
males aged 11 to 26 years during 2007–2014. We also examined age at first vaccine dose and age 
at first sexual activity among females aged 14 to 26 years. Vaccination significantly increased in 
females aged 13 to 26 years, but not among 11- to 12-year-old girls, and remained low for both 
females and males. In NHANES 2011–2014, among females with known age at first vaccine dose, 
43.1% reported having had sex before or in the same year they received their first HPV vaccine, 
and this varied by race/ethnicity. Clinicians should provide strong recommendations consistent 
with guidelines, including routine vaccination of girls and boys at age 11 or 12 years.
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Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection in the 
United States,1 occurring in approximately 39.5 million girls and women aged 14 to 59 
years with a prevalence of 32.9% among 14- to 19-year-olds and 53.8% among 20- to 24-
year-olds.2 Since 2006, the Advisory Committee on Immunization Practices (ACIP) has 
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recommended HPV vaccine for routine vaccination of girls aged 11 or 12 years and through 
age 26 years for those not previously vaccinated.3 This recommendation was extended in 
2011 to include routine vaccination of boys aged 11 or 12 years and through age 21 years for 
those not previously vaccinated.4 The vaccine is also recommended for men who have sex 
with men and immunocompromised men through age 26 years.4
Despite ACIP recommendations, the uptake of the HPV vaccine has been lower than other 
adolescent vaccines. In 2014, data from the National Immunization Survey (NIS)–Teen 
found that receipt of ≥1 HPV vaccine dose among girls and boys aged 13 to 17 years was 
60.0% and 41.7%, respectively; both estimates lagged behind those of tetanus, diphtheria, 
and acellular pertussis (Tdap) vaccine and meningococcal conjugate (Men ACWY) vaccine 
(87.6% and 79.3%, respectively).5 Findings from NIS-Teen also showed that ≥1 HPV 
vaccine dose coverage was lower among 13-year-old girls than 14- to 17-year-old girls.5 
Other studies suggest HPV vaccine initiation is delayed beyond the recommended ages of 11 
or 12 years.6
HPV incidence is high among young persons within the first few years after initiating sexual 
activity,7 and delaying HPV vaccine initiation leaves individuals vulnerable to vaccine-type 
HPV infection. In a recent study of a large urban population of females aged 11 to 19 years 
receiving their first dose of HPV vaccine, more than one-third had already undergone STD 
(sexually transmitted diseases) screening, suggesting prior sexual experience, and nearly 
one-third of those with cervical cancer screening already had an abnormal result, suggesting 
prior exposure to HPV.6
The National Health and Nutrition Examination Survey (NHANES) collects information on 
HPV vaccination history as well as sexual activity across birth cohorts eligible for HPV 
vaccination. We analyzed NHANES to describe HPV vaccination in females and males aged 
11 to 26 years and explore changes in vaccination among females during 2007–2014. We 
also assessed the timing of HPV vaccine initiation relative to age at first sexual activity 
among females during 2011–2014, the first years in which age at vaccination was collected 
in NHANES. We restricted our assessment of HPV vaccine initiation relative to age at first 
sexual activity among females because few males were vaccinated during the NHANES 
cycles we analyzed.
Methods
Study Population and Design
NHANES is an ongoing series of cross-sectional surveys conducted by the National Center 
for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). The 
survey is designed to be nationally representative of the civilian, noninstitutionalized US 
population. Participants have a household interview followed by a physical examination in a 
mobile examination center (MEC). NHANES data are released in 2-year cycles. Since 
NHANES 2011–2012, Asians have been oversam-pled in addition to the ongoing 
oversampling of Hispanics, non-Hispanic blacks, older adults, and low-income whites/
others.8 Written informed consent was obtained from all participants and parental 
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permission for participants <18 years. The survey was approved by the NCHS/CDC 
Research Ethics Review Board.
We analyzed NHANES 2007–2014 data. During 2007–2010, a total of 2155 females aged 
11 to 26 years were interviewed and 2103 (97.6%) were examined in the MEC. During 
2011–2014, a total of 2298 females and 2262 males aged 11 to 26 years were interviewed 
and 2210 (96.2%) females and 2194 (97.0%) males were examined in the MEC.
Sociodemographic, Behavioral, and HPV Vaccination History
Sociodemographic information and report of HPV vaccination were obtained during the 
household interview. Participants aged ≥16 years and emancipated minors were interviewed 
directly while information for participants aged <16 years was provided by a parent or 
guardian. Race/ethnicity in NHANES 2007–2014 was self-reported and included non-
Hispanic black, non-Hispanic white, Mexican American, and Asian. Poverty index was 
calculated according to the US Health and Human Services poverty guideline by dividing 
total family income by the poverty guideline and adjusting for family size and geographic 
location. We categorized responses about health insurance as public/government, private, or 
no insurance. Sexual history was obtained directly from participants aged 14 to 69 years 
through Audio-Computer-Assisted Self Interview conducted in the MEC. Sex was defined as 
vaginal, anal, or oral sex. Respondents who reported ever having sex were asked how old 
they were the first time they had sex.
Report of HPV vaccination has been collected from females aged 9 to 59 years since 2007 
and males aged 9 to 59 years since 2011. The question to assess vaccination was “Human 
papillomavirus (HPV) vaccine is given to prevent cervical cancer in girls and women [HPV 
infection and genital warts in boys and men] … It is given in 3 separate doses over a 6-
month period. {Have you/has SP [selected participant]} ever received one or more doses of 
the HPV vaccine?” Answers included “yes,” “no,” “refuse,” and “don’t know.” Persons with 
missing data or who answered “refuse” or “don’t know” were excluded (3.3% of females 
during 2007–2014 and 10.1% of males during 2011–2014). Those who answered “yes” to 
HPV vaccination were asked the number of doses received. Age at first dose of HPV vaccine 
has been collected since 2011 for both sexes.
Statistical Analysis
Our analysis included female and male participants aged 11 to 26 years. We evaluated HPV 
vaccination (receipt of ≥1 and 3 doses of HPV vaccine) by age group for females (11–12, 
13–17, and 18–26 years) during 2007–2014 and males (11–12, 13–17, 18–21, and 22–26 
years) during 2011–2014. We assessed vaccination across NHANES cycles among females 
to compare changes in vaccination by age group from the first 4 years (2007–2010) to the 
last 4 years (2011–2014). Sociodemographic characteristics among females were assessed in 
three age categories: 11–12 years, selected to include the recommended age group for 
routine HPV vaccination; 13–17 years, selected to include the age group assessed by NIS-
Teen;9 and 18–26 years, selected to include the remaining ages eligible for HPV vaccination 
and for closely corresponding to the age group of 19–26 years analyzed in the National 
Health Interview Survey (NHIS).10 We calculated P values based on an F statistic derived 
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from a Wald χ2 test. We examined differences in mean age at first dose of HPV vaccine and 
mean age at first sexual activity among females aged 14–26 years by race/ethnicity and 
determined the percentage of vaccinated females who reported having had sex for the first 
time before or in the same year as their first vaccine dose. We combined those reporting first 
sexual activity in the same year as their first dose of HPV vaccine with those reporting sex 
before their first dose of HPV vaccine as we were unable to determine if the first vaccine 
dose was received before first sexual activity if in the same year.
Statistical analyses were conducted using SAS 9.3 (SAS, Inc, Cary, NC) and SAS-callable 
SUDAAN 11.0 (Research Triangle Institute, Research Triangle Park, NC). Standard errors 
accounted for the complex survey design. Estimates were weighted using the weights 
provided by NCHS for survey years 2007–2014 to be nationally representative. Sample 
weights accounted for nonresponse to the interview and medical examination and 
oversampling of certain populations.8,11 Statistical significance was set at a 2-tailed P value 
of .05.
Results
History of ≥1 and 3 HPV Vaccine Doses by Age Group, 2007–2014
A total of 4276 (96.9%) females and 2046 (89.9%) males aged 11–26 years responded to the 
question on HPV vaccine receipt. Vaccination among females significantly increased 
between the 2 time periods among the older age groups but not among 11- to 12-year-olds 
(Figure 1 and Table 1). Vaccination with ≥1 dose among 11- to 12-year-olds was 16.4% in 
2007–2010 and 22.3% in 2011–2014 (P = .2). For the older age groups, vaccination with ≥1 
dose significantly increased from 30.6% to 53.2% in 13- to 17-year-olds and 19.2% to 
39.9% in 18- to 26-year-olds (P < .01). A similar pattern was observed for 3 doses, with 
5.4% (95% confidence interval [CI] = 3.3–8.6) of 11- to 12-year-olds having completed the 
vaccine series in 2007–2010 and 6.4% (95% CI = 3.3–12.3) in 2011–2014 (P = .2). For the 
older age groups, HPV vaccination with 3 doses significantly increased from 17.2% (95% CI 
= 13.5–22.2) to 33.8% (95% CI = 28.9–39.1) in 13- to 17-year-olds and 10.6% (95% CI = 
7.3–15.1) to 24.9% (95% CI = 21.1–29.1) in 18- to 26-year-olds (P < .01).
Among males, HPV vaccination with ≥1 dose in 2011–2014 was 19.4% (95% CI = 15.0–
24.6) in 11- to 12-year-olds, 20.2% (95% CI = 16.4–24.6) in 13- to 17-year-olds, 15.3% 
(95% CI = 11.7–19.7) in 18- to 21-year-old, and 7.5% (95% CI = 5.7–10.0) in 22- to 26-
year-olds. Vaccination with 3 doses was 5.8% (95% CI = 3.8–8.9) in 11- to 12-year-olds, 
9.5% (95% CI = 6.9–13.0) in 13- to 17-year-olds, 7.3% (95% CI = 4.9–10.7) in 18- to 21-
year-olds, and 3.2% (95% CI = 1.4–7.4) in 22- to 26-year-olds.
History of ≥1 HPV Vaccine Dose Among Females by Sociodemographic Characteristics 
and Age Group
HPV vaccination with ≥1 dose among girls aged 11 to 12 years varied by race/ethnicity in 
2007–2010 (Table 1, panel A); coverage was highest among non-Hispanic blacks (30.5%) 
and lowest among non-Hispanic whites (9.0%) (P < .001). There was variation by race/
ethnicity during 2011–2014, but differences were not statistically significant. History of ≥1 
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dose did not differ by health insurance type in 2007–2010, but differed during the later 
period. In 2011–2014, this was highest among those with public/government insurance 
(31.9%) and lowest among those with no insurance (14.8%) (P = .013). There were 
differences by poverty level in both time periods, with a larger proportion of those below 
poverty reporting vaccination with ≥1 dose compared with those at or above poverty.
Among girls aged 13 to 17 years, history of ≥1 HPV vaccine dose significantly increased 
between the 2 time periods in all subgroups (Table 1, panel B). There was variation by race/
ethnicity during 2007–2010, but differences were not statistically significant. In 2011–2014, 
history of ≥1 dose was highest among Mexican Americans (60.0%) and lowest among 
Asians (40.0%) (P = .04). History of ≥1 dose varied significantly by health insurance type in 
2007–2010 and was highest among those with public/government insurance (33.4%) and 
lowest among those with no insurance (11.9%) (P < .01). There were no differences by 
health insurance in 2011–2014 and no difference by poverty level in either of the time 
periods examined.
Among women aged 18 to 26 years, history of ≥1 vaccine dose significantly increased 
between the 2 time periods in all subgroups (Table 1, panel C). There was variation by race/
ethnicity in both time periods, but differences were not statistically significant. History of ≥1 
vaccine dose significantly differed by health insurance in 2007–2010 and was highest among 
those with private insurance (25.2%) and lowest among those with no insurance (10.0%) (P 
< .01). In 2011–2014 there were no differences between those with public/government 
insurance (43.2%) or private insurance (43.0%), but history of ≥1 vaccine dose was lower in 
those with no insurance (29.8%) (P = .01). There was no difference by poverty level in either 
of the time periods examined. We further examined age at vaccination among women aged 
18 to 26 years in 2011–2014; the median age at first vaccine dose was 16.9 years, and 34.8% 
(95% CI = 27.5–43.0) reported that they had received the first dose at age 19 years or older.
Age at First HPV Vaccine Dose and Age at First Sexual Activity Among Females Aged 14–
26 Years, 2011–2014
Among 1069 females aged 14 to 26 years who reported having received HPV vaccine, 
95.3% provided age at first dose. Among 953 females who reported ever having sex, 99.8% 
provided age at first sexual activity. Among females with known age at first HPV vaccine 
dose, 43.1% reported having had sex before or in the same year as their first HPV 
vaccination. This varied by race/ethnicity, and was higher among non-Hispanic blacks 
(52.5%) than non-Hispanic whites (42.2%), Mexican Americans (33.3%), and Asians 
(30.9%) (P < .001). Mean age at first HPV vaccine dose and mean age at first sexual activity 
by race/ethnicity are shown in Table 2. Mean age at first HPV vaccine dose was older than 
mean age at first sex among non-Hispanic blacks.
Discussion
Using self- or parent-reported data from a nationally representative survey, we found HPV 
vaccination with ≥1 dose and 3 doses among females aged 13 to 26 years significantly 
increased between 2007–2010 and 2011–2014. However, there was no change in vaccination 
among girls aged 11 to 12 years, and coverage remained low for both females and males. 
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More than 40% of females with known age at first vaccine dose reported having had sex for 
the first time before or in the same year they received their first HPV vaccination, which is 
important because exposure to HPV prior to vaccination may reduce vaccine effectiveness.
Our data on coverage with ≥1 HPV vaccine dose are generally consistent with those of other 
national surveys for those aged 13 to 17 years and 18 to 26 years. In NHANES 2011–2014, 
HPV vaccine initiation among girls aged 13 to 17 years was 53%, similar to estimates from 
NIS-Teen, which ranged from 53% in 201112 to 60% in 2014.5 Variation between these 2 
surveys could be due to the use of self- or parent-report of HPV vaccination in NHANES11 
compared with provider-verified records in NIS-Teen.9 Among women aged 18 to 26 years 
in NHANES 2011–2014, 40% reported having received at least one HPV vaccine dose. 
Among 19- to 26-year-olds in NHIS, which also uses self-reported vaccination history, 
estimates ranged from 29.5% in 201113 to 40% in 2014.10 However, among 11- to 12-year-
olds, our data show lower coverage than a recent study using a birth cohort analysis.14 That 
analysis reported 47% of girls aged 13 years in 2013 had received ≥1 dose of HPV vaccine 
before they reached age 13.
We found that coverage with ≥1 HPV vaccine dose by sociodemographic factors and 
insurance differed by age group. In 11- to 12-year-old girls, coverage with ≥1 dose was 
highest among non-Hispanic blacks and lowest among non-Hispanic whites in 2007–2010; a 
similar pattern, although not statistically significant, was observed in 2011–2014. Among 
girls aged 13 to 17 years, coverage with ≥1 dose in 2011–2014 was highest among Mexican 
Americans (60%) and lowest among Asians (40%). NIS-Teen 2014 similarly found ≥1 dose 
coverage among girls aged 13 to 17 years to be lowest in Asians and high among Hispanics 
(66.3%) and non-Hispanic blacks (66.4%).5 Among 18- to 26-year-olds, variation by race/
ethnicity was not statistically significant in either time period we examined whereas HPV 
vaccine initiation among females was significantly higher among non-Hispanic whites than 
other racial/ethnic groups in NHIS 2008–2012.15
Report of ≥1 dose among 11- to 12-year-old girls with public/government insurance was 
nearly twice as high compared with those with private or no insurance, but there was no 
difference by type of health insurance for girls aged 13 to 17 years. In both time periods, a 
significantly higher proportion of 11- to 12-year-olds below poverty reported ≥1 dose 
coverage compared with those at or above poverty. Among girls aged 13 to 17 years and 
women aged 18 to 26 years, differences by poverty were not observed. Our findings for girls 
aged 13 to 17 years differ from NIS-Teen, which found ≥1 dose to be higher among those 
below poverty,5 but are similar to findings from other studies in adult women of comparable 
age groups.13,16,17
Our findings as well as other studies indicate that black and Hispanic, low-income, and 
publicly insured adolescents initiate the HPV vaccine at equivalent or higher rates than 
white, higher income adolescents.15,18,19 These findings may be due to the availability of the 
vaccine through the Vaccines for Children (VFC) program and/or to lower refusal rates in 
these groups.20 VFC provides vaccines for uninsured, Medicaid-eligible children aged 18 
years and younger.21 While higher vaccine coverage in these groups will help decrease 
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disparities in HPV-associated disease, increases in vaccine coverage are needed in all 
sociodemographic groups.
In our study, report of ≥1 HPV vaccine dose among women aged 18 to 26 years increased 
regardless of health insurance type. While the increase in vaccination in this age group was 
due, in part, to girls vaccinated when they were younger entering this age group, 
approximately one-third of women who had initiated the vaccine series reported they 
received the first vaccine at age 19 years or older. The provisions of the Affordable Care Act 
(ACA) passed in 2010 require insurance plans to offer dependent coverage through age 25 
years and provide targeted preventive services with zero cost sharing.22 Other studies have 
reported that ACA was associated with a significant increase in the percentage of young 
adult women aged 19 to 25 years initiating HPV vaccination.23
We were able to examine the timing of first dose of HPV vaccine and first sexual activity 
using data from NHANES 2011–2014. Among females aged 14 to 26 years with known age 
at first HPV vaccine dose, 43% reported first sexual activity before or in the same year they 
received their first HPV vaccine, and this varied by race/ethnicity, being highest in non-
Hispanic blacks. Vaccination after first sexual activity could decrease the benefit of 
vaccination and lower estimates of vaccine effectiveness in the early vaccine era. Many of 
the vaccinated individuals in the survey were older than the recommended age for 
vaccination when HPV vaccine became available in the United States. As more girls are 
vaccinated at the recommended age for routine vaccination, the proportion of females 
already sexually active at the time they receive their first HPV vaccine dose should decrease.
Parents may decline or defer HPV vaccination due to concerns over vaccine safety, beliefs 
about the age-related need for vaccination, and perceived low-infection risk.24,25 Studies 
indicate that both parents and providers may underestimate adolescent sexual 
experience,26–28 highlighting the importance of vaccinating by the recommended ages when 
adolescents are less likely to have initiated sexual activity.29 Some parents may worry that 
HPV vaccination could lead to behavioral disinhibition and risky sexual behaviors,30 
although studies have not found this to occur.31 Strong provider recommendations are highly 
influential for vaccination uptake,32 but providers may prefer to recommend HPV 
vaccination in older rather than younger adolescents as they may perceive younger 
adolescents to be at low risk for HPV infection and may be concerned about negative 
parental reactions.33–35 To facilitate timely vaccination, clinicians should provide strong 
recommendations consistent with guidelines, including administration of the vaccine the 
same day as other adolescent vaccines, and emphasize the vaccine’s protection against 
cancer and vaccine safety.
This study has some limitations. First, HPV vaccination was self- or parent-reported and 
subject to reporting bias. However, our findings were similar to other surveys.9,10 Second, 
we analyzed vaccination with ≥1 dose at age 11 or 12 years; therefore, our estimate will be 
lower than estimates of vaccine initiation by age 13 years.14 Third, our estimates for mean 
age at first sexual activity may have been lower than the true mean age at first sex because 
we could only include data from those who had sex at the time of the survey. Fourth, we 
were unable to determine if sex occurred before vaccination for those reporting first sexual 
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activity in the same year as their first dose of HPV vaccine, and we chose to combine this 
subgroup with those reporting sex before their first dose of HPV vaccine. Last, the small 
sample size in some groups limited our ability to conduct further analyses: we were unable 
to assess if HPV vaccination before having sex varied by age and there was an insufficient 
number of Asians to form a separate race category during 2007–2010 because this group 
was not oversampled.
Conclusion
This study used data from a nationally representative survey that includes vaccination 
history across a wider age range than available from other national surveys. There were 
significant increases in HPV vaccination among females aged 13 to 26 years in the 8 years 
following vaccine licensure. However, there was no change in vaccination among girls aged 
11 to 12 years. Coverage remained low for both females and males in all age groups we 
examined. Among females with known age at first vaccine dose, 43% in 2011–2014 
reported having had sex before or the same year they received their first HPV vaccine, which 
may decrease the initial population level impact of HPV vaccination. Clinicians should 
provide strong recommendations consistent with guidelines, including routine vaccination of 
girls and boys at age 11 or 12 years.
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Figure 1. 
History of ≥1 and 3 human papillomavirus (HPV) vaccine doses among females aged 11 to 
26 yearsa,b by age group, National Health and Nutrition Examination Survey, 2007–2014.
aAt the time of the survey.
bIncludes participants who responded “Yes” or “No” to the HPV vaccination question.
* Significantly increased among females aged 13 to 17 and 18 to 26 years (P < .01).
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Table 2
Age at First Human Papillomavirus (HPV) Vaccine Dose and Age at First Sexual Activity Among Females 
Aged 14–26 Yearsa by Race/Ethnicity, National Health and Nutrition Examination Survey, 2011–2014.
Age (Years) at First HPV Vaccine Dose, Mean (SD) Age (Years) at First Sexual Activity, Mean (SD)
Overall 15.9 (0.2) 16.2 (0.1)
Race/Ethnicity
 White, non-Hispanic 15.8 (0.3) 16.2 (0.1)
 Black, non-Hispanic 16.2 (0.2) 15.8 (0.1)
 Mexican American 15.1 (0.4) 16.0 (0.2)
 Asian 16.7 (0.5) 17.9 (0.4)
aAt the time of the survey.
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